ArticleWorld journal of urology2026
Does perioperative chemotherapy affect renal function after radical nephroureterectomy for upper tract urothelial carcinoma?
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the impact of perioperative chemotherapy (PC) on short and mid-term estimated glomerular function rate (eGFR) in patients treated by radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).
methodsA retrospective multicenter study was conducted in all consecutive UTUC patients treated by RNU with or without PC between 2013 and 2022 in 3 French hospitals. eGFR (CKD-EPI formula) were collected in pre and post-operatively until 24 months after RNU. Pre and post RNU eGFR were compared according to the administration of PC. Univariable and multivariable logistic regression models were used to investigate predictors of eGFR < 60 mL/min/1.73m2 at short-term (6 months after RNU) and mid-term (18–24 months after RNU). Finally, the kidney failure free survival was computed for each group, according to the competing risk of death.
resultsAmong 231 RNU, 53 (23%) were treated with PC including 29 (55%) neoadjuvant chemotherapy and 24 (45%) adjuvant chemotherapy. The preoperative median eGFR tended to be higher in the PC group (69.5 vs. 65 mL/min/1.73 m², p = 0.07), with a lower rate of renal failure (20.7% vs. 33.1%, p = 0.04). At mid-term after RNU, the median ΔeGFR compared to preoperative surgery was − 18 mL/min/1.73 m2, similar in PC and non-PC group (p = 0.9). In univariate logistic regression, PC do not show a statistically significant effect on eGFR < 60 ml/min at short (OR = 1.2 95%CI:0.54–2.79, p = 0.7) and mid-term (OR = 1.14 95%CI: 0.48–2.78, p = 0.8). According to the competing risk of death, the three-years kidney failure free survival was 11.8 [3.8; 36.4] % and 14.0 [7.31; 26.9] % for PC and no-PC group, respectively (p = 0.3).
conclusionAdministration of PC was not associated with a decline in renal function within two years following RNU.
Indexed as
Identifiers
41670683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.